Article Text

Download PDFPDF
Three cases of advanced cutaneous squamous cell carcinoma treated with a combination of carboplatin and epirubicin
  1. Mayumi Okamoto,
  2. Takanobu Kan,
  3. Emi Murakami,
  4. Tomofumi Numata,
  5. Risa Otsuka,
  6. Manami Sueoka,
  7. Masaya Moriwaki,
  8. Shunsuke Takahagi,
  9. Akio Tanaka,
  10. Mikio Kawai,
  11. Hayato Mizuno,
  12. Michihiro Hide
  1. Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  1. Correspondence to Professor Michihiro Hide, Hiroshima, Japan; ed1h-w1de-road{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Advanced cutaneous squamous cell carcinoma (cSCC) with nodal and/or distal metastases or large local spreading is inoperable, and treatment options for patients are usually limited to chemotherapy and radiation. The National Comprehensive Cancer Network (NCCN) Guidelines include some regimens of cisplatin- (CDDP) based systemic therapies, but no chemotherapy has yet been established for advanced cSCC.1 Peplomycin sulfate, bleomycin, and irinotecan are licensed for cSCC in Japan but are not commonly used in actual clinical practice because of their low efficacy and severe side effects (such as interstitial pneumonia, myelosuppression, and adverse digestive symptoms). CA regimen, the combination of CDDP and adriamycin (ADM), has been reported to show a response rate of about 60% for advanced cSCC,2 whereas other …

View Full Text


  • Contributors MO, TK, MK and MH designed the study. MO, TK, EM, TN, RO, MS and MM contributed to the data collection. MO, TK, ST, AT, MK, HM and MH contributed to analysis and interpretation of data, and assisted in the preparation of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer-reviewed.